Introductionstudy, 6 as well as the remainder of the MHC, have not been studied in pediatric-onset MS (POMS). Sorting out which adult MS risk variants are associated with onset in childhood will help determine whether the genetic contributions to the development of MS pathology occur irrespective of age. In addition, identifying variants with larger effects in POMS could point to critical biological pathways determining an earlier onset. The goal of this study was to (1) determine whether established MS risk variants from genome-wide association studies (GWAS) in adults are also associated with POMS and have higher effect sizes, (2) to study HLA-DRB1*15, HLA-A*02 and the MHC region in POMS using high-density singlenucleotide polymorphism (SNP) genotyping, (3) to directly compare results from pediatric-onset and adult cases for differences in overall genetic burden and effect size, and (4) to determine whether genetic risk variants are associated with age of onset in POMS cases.
Methods

US participants POMS cases were enrolled through pediatric MS centers established across the United States between January 2006 and December 2014 (Supplementary Appendix 1)
. Consecutive patients with onset of MS or clinically isolated syndrome suggestive of early MS before the age of 18 years seen at some of these pediatric MS clinics were offered participation as previously described. 7 In addition, we utilized adult cases from Kaiser Permanente Northern California (KPNC) with reported age of first symptom onset <18 years. 8 Age of onset of MS was determined as year of first self-reported clinical symptom, based on the following questions: "How old were you when you had your first clinical symptoms of MS?" and "What were your first clinical symptoms of MS?" Year of disease onset was calculated using date of birth and was verified in the medical record when possible. KPNC MS cases with age of onset > 18 years were included for comparison in the study (n = 1103). 8 Established diagnostic criteria were used for all pediatric (n = 738) 9 and adult-onset cases (n = 1103). 10, 11 Control individuals without a diagnosis of MS or related condition (optic neuritis, transverse myelitis, or demyelination disease) were recruited from Northern California, 8 including individuals from the Genetic Epidemiology Research on Adult Health and Aging cohort who participated in the KPNC Research Program on Genes, Environment, and Health (RPGEH; dbGaP phs000674.v2.p2), and controls recruited as part of a pediatric MS case-control study (total = 12,300). 12 Swedish participants Data were collected from two population-based casecontrol studies in Sweden of incident (Epidemiological Investigation of MS (EIMS)) and prevalent (Genes and Environment in MS (GEMS)) MS patients. The EIMS study (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) inclusion criteria were as follows: age = 16-70 years, diagnosed MS according to the McDonald criteria 10,11 within 2 years, and ability to understand the Swedish language. GEMS study participants were identified from the Swedish National MS registry, fulfilled the McDonald criteria, and were recruited during 2009-2011. For both studies, controls were randomly chosen from the population register and matched to cases by sex, age at inclusion in the study, and region of residence. Two controls were matched to each case in the EIMS study and one control per case in the GEMS study. All participants in the EIMS study were distinct from those in the GEMS study. Details of the study design have been described elsewhere. 13 Age of onset of MS was determined as year of first self-reported clinical symptom and confirmed when possible, as described above. Data for 175 POMS cases (reported age of onset <18 years), 6485 adult-onset MS cases, and 5376 controls were available for the current study. 
Standard protocol approvals
Statistical analyses
Genotyping and quality control procedures are outlined in the supplemental materials (Supplementary Appendix 2). Characterization of HLA-DRB1*15 was assessed for each study participant; for the US study, a tag SNP (rs3135388) was used. 14 Whole-genome data were used to test the previously established 110 MS GWAS SNP genotypes 6 for association with POMS. Each SNP genotype was considered as zero, one, or two minor alleles (additive effect) for analysis. Furthermore, a weighted genetic risk score (wGRS) that combines the weighted odds ratio (OR) from each of 110 non-MHC MS susceptibility loci was calculated for each pediatric-onset case and control by multiplying the number of risk alleles for each locus by the weight for that variant and then taking the sum across the 110 loci. 15 The weight for each locus is the natural log of the OR for each allele. Of the 110 SNPs, 3 were missing in the US study (rs201202118, rs201847125 and imm_5_141486748) and 1 SNP failed Hardy-Weinberg equilibrium (rs2744148). Of the 110 SNPs, 3 were missing from the Swedish data (rs2028597, rs4679081, and imm_5_141486748). Adequate SNP tagging proxies were not identified; therefore, these six SNPs were not included in the individual SNP meta-analyses or each cohort's respective wGRS.
Logistic regression modeling was used adjusting for genetic ancestry and other covariates when noted for case-control analyses; 95% confidence intervals (CI), allelic OR (unless otherwise noted), and two-sided p-values were reported. For the MHC region, individual variants were analyzed spanning 6p22.1 to 6p21.3 (~29 to 33 Mb on hg19 assembly). Metaanalyses were performed under a random-effects model. Linear regression was performed in case-only analyses with age of onset as the outcome; values were transformed to the fifth power (x 5 ) to normalize the negatively skewed distribution. All analyses were performed in PLINK v.1.07 or R v.3.2.2. Because the study of candidate SNPs and wGRS was strongly hypothesis based, we used p < 0.05 as a type I error rate for reporting significance. For the MHC region analyses (beyond HLA-DRB1*15:01 and HLA-A2), the number of independent MHC haplotype blocks was used to control for multiple comparisons and guide interpretation of results.
Role of funding source
Funding sources listed below (see Acknowledgements) had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
Results
Subject characteristics
We restricted our study sample to White non-Hispanic individuals (European ancestry), the largest group in our dataset, to ensure a genetically homogeneous sample and avoid the possibility of confounding by genetic ancestry (Supplementary Figure 1) . After excluding population outliers, the final dataset comprised 394 POMS cases and 10,875 controls from the United States, as well as 175 POMS cases and 5376 controls from Sweden (total N = 16,820). Demographic features and clinical characteristics of participants are shown in Table 1 . Mean age at symptom onset for POMS cases was 14.05 years (±3.30 years) in the US study and 14.91 (±2.67) in the Swedish study. We also included 1103 and 6485 adult-onset MS cases from the United States and Sweden, respectively (total N = 7588), for comparison of genetic associations observed in POMS (Supplementary Table 1 ).
Established non-MHC MS genetic risk variants
Results from the meta-analysis of MS variants identified in recent GWAS demonstrated that 28 of 104 established MS SNPs tested were significantly [17] [18] [19] [20] Through fine mapping of the MHC region in this study, we observed only modest evidence for HLA-A*02 effect in POMS.
Strong evidence for independent class II and III effects was detected, similar to findings from a previous study of adult MS cases and controls for which 11 independent associations within the MHC were reported. 18 In this study, several SNPs within/near NOTCH4 in the class III region provided the strongest evidence for association after accounting for HLA-DRB1*15:01 and correction for multiple comparisons, with one SNP (rs438475) demonstrating high evidence of functionality as an expression quantitative trait locus and transcription factor binding site. Nominal evidence for class II effects was also present, including two SNPs (rs3129888 and rs2395182) identified as expression quantitative trait loci and transcription factor binding sites. The human MHC class III region is the most gene-dense region of the human genome. 21 Variation within NOTCH4 has been shown recently to decrease the risk of developing MS in Japanese adults, 22 ,23 similar to our finding, but in contrast to another. 24 Taken together, the involvement in POMS susceptibility of HLA-DRB1*15:01 and one or more gene variants within the class III MHC region is strongly supported. MHC region and classical HLA loci genotyping is needed in a larger dataset to fully characterize the MHC contribution to POMS, which, similar to adult studies, appears to be complex. 18, 25 For the first time, we studied individual and collective associations between 104 of the 110 established non-MHC adult MS risk variants 6 and susceptibility to POMS. In all, 28 variants were significantly associated at p < 0.05; several variants had larger effect estimates compared to published results from the adult MS studies. Top SNPs included rs74796499 within GALC and rs9828629 in FOXP1, both involved in nervous system development. We found a significant inverse association between an SNP in BACH2 and POMS, which has been shown to increase the risk of MS in adults; further work and replication are needed to confirm the difference in directionality between the two populations. A significantly higher wGRS was also observed in POMS cases compared to controls in both US and Swedish datasets after adjusting for genetic ancestry and HLA-DRB1*15:01, in agreement with a small study that used a subset of the 110 MS risk variants to construct a 57 SNP wGRS. 26 We did not find an association between wGRS and age of pediatric disease onset, which has been previously reported for adult-onset MS. 27 One reason why an association with age of onset in children may not have been found is that the range was limited (age = 4-17 years included). Nevertheless, these findings warrant further investigation.
Whether HLA-DRB1*15:01 is associated with earlier age of symptom onset in adult MS has been the subject of several investigations. Strong evidence supports the hypothesis that HLA-DRB1*15:01 is indeed associated with an earlier onset in adults; [28] [29] [30] though conflicting findings have been reported, including one large 6 and two small studies with <100 patients. 4, 31 In this study, we did not observe a relationship between HLA-DRB1*15:01 and age of onset in POMS cases. When we compared the cases with symptom onset <18 years of age to cases with symptom onset >18 years of age, HLA-DRB1*15:01 allele distribution differences were present in the Swedish but not US dataset.
Our study had several important strengths. Rigorously diagnosed and clinically well-characterized POMS cases with symptom onset ~20 years earlier than most adult MS cases were studied. In addition, a wellpowered analysis of HLA-DRB1*15:01 and 104 established MS risk variants was considered for the first time in POMS, and a comparison with adult cases was included. We studied the MHC region with highdensity SNP mapping in POMS which has not been previously attempted. Genetic diversity among POMS cases is well established, and the potential for population stratification in a case-control study leading to false-positive findings is high. Our initial patient group included representatives from non-White populations (n = 320; 43% of cases). Comprehensive methods, including multi-dimensional scaling, were used to identify these subgroups, and we restricted this study to White/European, non-Hispanic individuals for increased genetic homogeneity (Supplementary Appendix 2). We also adjusted for genetic ancestry within Europeans in our models when necessary.
Some limitations of this study must also be acknowledged. POMS cases were identified through tertiary clinics and may not represent all MS cases with onset in childhood. It is possible that individuals with a more benign disease or without access to healthcare may have been missed. While many of our POMS cases were diagnosed as children in a clinical setting (n = 130), some reported the onset of their first disease symptoms in childhood and/or data were extracted from medical records regarding timing of first symptoms but were ascertained as adults. We stratified these groups for comparison to detect any clinical or genetic differences that may have biased our findings (Supplementary Table 4) . Notably, MS patients diagnosed as children in the clinic (United States) had a slightly lower mean age of symptom onset compared to patients with pediatric symptom onset who were recruited as adults (United States and Sweden); this patient group also had a lower frequency of HLA-DRB1*15:01 and average wGRS compared to other groups; though as reported, the patient group as a whole (<18 years of age at onset) had a significantly higher wGRS and HLA-DRB1*15:01 frequency when compared to controls. The possibility of two genetically distinct MS patient groups-one with symptom onset in early childhood-and one with symptom onset in late teen/early adulthood is one to strongly consider, given the findings presented in this study. We were unable to complete well-powered stratified analyses based on adolescence due to the limited sample size of cases. Other factors may have a stronger influence on disease onset in younger MS patients, such as yet unidentified genetic loci or environmental factors, as previously suggested. 3 Due to the unavailability of environmental exposures for a substantial portion of our control group, we were unable to additionally adjust for this information. These factors may be more influential in triggering symptoms of MS in early childhood, given that prenatal, perinatal, and early childhood windows represent a period of vulnerability to exposures.
MS onset in childhood is a rare occurrence, and thus, our case sample was small compared to genetic studies in adult disease. It is possible that very modest effects for less common alleles may have been missed due to our sample size. While this study had >85% power to detect associations with ORs >1.25 and <0.80 for the 110 candidate SNP analysis in the combined meta-analysis (minor allele frequency of 0.20, p = 0.05), certain candidates may have been missed due to lack of power. The results presented here will need to be replicated in a larger dataset. Finally, our study was restricted to White/European, non-Hispanics. Examination of rare variants and established European MS genetic risk variants in non-White patient groups is needed to further the understanding of MS pathogenesis, as well as focused studies to identify population-specific risk variants.
In conclusion, we confirmed a role for several previously identified adult-onset MS genetic risk factors in the development of pediatric-onset disease and identified stronger effects of some variants compared to adult-onset MS. Comprehensive assessment of genome-wide associations in POMS, as well as interaction between genetic and environmental exposures, will be important to further characterize POMS susceptibility and are currently underway.
